The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints which are important for the patient such as over all survival and side effects.

Condition
Uterus Cancer

Further Study Details: 

Expected Total Enrollment:  99

It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors.Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to draw blood in MAASTRO clinic of all patients with uterus cancer and store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

cancer of the uterus

Exclusion Criteria:

not able to comply with follow-up

-

Please refer to this study by ClinicalTrials.gov identifier  NCT00157469

Philippe Lambin, Prof PHD      +31 (0) 43 387 44 54    philippe.lambin@maastro.nl
Dirk De Ruysscher, PHD      +31 (0) 45 577 12 00    dirk.deruysscher@maastro.nl

Netherlands, Limburg
      Maastricht Radiation Oncology, HEERLEN,  Limburg,  6419 PC,  Netherlands; Recruiting

Study chairs or principal investigators

Dirk De Ruysscher, PHD,  Principal Investigator,  CCMO   

Study ID Numbers:  P05.0750L
Last Updated:  September 10, 2005
Record first received:  September 8, 2005
ClinicalTrials.gov Identifier:  NCT00157469
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
ClinicalTrials.gov processed this record on 2005-09-13